Two-year follow-up of a prospective study of circulating regulatory T cells in renal transplant patients

Clinical Transplantation

Volumn 24, Issue 3, 2010, Pages 386-393

  Segundo, David San ^a   Fernández Fresnedo, Gema ^a   Ruiz, Juan C ^a   Rodrigo, Emilio ^a   Benito, María J ^a   Arias, Manuel ^a   López Hoyos, Marcos ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Clinical utility; Follow up; Immunosuppression; Regulatory T cells; Renal transplantation

Indexed keywords

CD16 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; L SELECTIN; LYMPHOCYTE ANTIGEN RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; T LYMPHOCYTE ANTIBODY; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CADAVER KIDNEY; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; BLOOD; HISTOCOMPATIBILITY; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; TIME; TRANSPLANTATION TOLERANCE;

BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 77954170937     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01086.x     Document Type: Article

References (33)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4:378.
2. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326.
3. Cantarovich D, Vistoli F, Soulillou JP. Immunosuppression minimization in kidney transplantation. Front Biosci 2008, 13:1413.
4. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199.
5. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345.
6. Manavalan JS, Kim-Schulze S, Scotto L. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004, 16:1055.
7. Jiang X, Kojo S, Harada M, Ohkohchi N, Taniguchi M, Seino K-I. Mechanism of NKT cell-mediated transplant tolerance. Am J Transplant 2007, 7:1482.
8. Bestard O, Cruzado J, Mestre M. Achieving donor-specific hyporesponsiveness is associated with Foxp3+ regulatory T-cell recruitment in human renal allograft infiltrates. J Immunol 2007, 179:4901.
9. Noris M, Casiraghi F, Todeschini M. Regulatory T cells and T-cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007, 18:1007.
10. Joffre O, Santolaria T, Calise D. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008, 14:88.
11. Benghiat FS, Graca L, Braun MY. Critical influence of natural regulatory CD25+ T cells on the fate of allografts in the absence of immunosuppression. Transplantation 2005, 79:648.
12. Segundo DS, Ruiz JC, Izquierdo M. Calcineurin inhibitors, but not rapamycin, reduce percentage of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006, 82:550.
13. Baan CC, Velthuis JH, van Gurp EA. Functional CD25 (bright+) alloresponsive T cells in fully immunosuppressed renal allograft recipients. Clin Transplant 2007, 21:63.
14. Demirkiran A, Hendriks TK, Baan CC, van der Laan LJW. Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to the clinical setting? Transplantation 2008, 85:783.
15. Loong CC, Hsieh HG, Liu WY, Chen A, Lin CY. Evidence for early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002, 197:322.
16. Hsieh HG, Loong CC, Lui WY, Chen A, Lin CY. IL-17 expression as a possible predictive parameter for subclinical allograft rejection. Transpl Int 2001, 14:287.
17. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD24+FoxP3+ regulatory T cells. Blood 2005, 105:4743.
18. Baan CC, van der Mast BJ, Klepper M. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005, 80:110.
19. Coenen JA, Koenen HJPM, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporine A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006, 107:1018.
20. Valmori D, Tosello V, Souleimanian NE. Rapamycin mediated enrichment of T cells with regulatory activity in stimulated CD4+ T-cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 2006, 177:944.
21. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007, 7:1722.
22. San Segundo D, Fabrega E, Lopez-Hoyos M, Pons F. Reduced numbers of blood natural regulatory T cells in stable liver tranplant recipients with high levels of calcineurin inhibitors. Transplant Proc 2007, 39:2290.
23. Kreijveld E, Koenen HJPM, Klasen IS, Hilbrands LB, Joosten I. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007, 7:249.
24. Kreijveld E, Koenen HJPM, van Cranenbroek B, van Rijssen E, Joosten I, Hilbrands LB. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS One 2008, 3:e2711.
25. Veronese F, Rotman S, Smith RN. Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. Am J Transplant 2007, 7:914.
26. Bestard O, Cruzado JM, Rama I. Presence of FoxP3+ regulatory T cells predicts outcome of subclinical rejection in renal allografts. J Am Soc Nephrol 2008, 19:2020.
27. Bestard O, Nickel P, Cruzado JM. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008, 19:1419.
28. Braudeau C, Racape M, Giral M. Variation in mumbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transplant Int 2007, 20:845.
29. Daniel V, Naujokat C, Sadeghi M. Observational support for an immunoregulatory role of CD3+CD4+CD25+IFN-gamma+ blood lymphocytes in kidney transplant recipients with good long-term graft outcome. Transplant Int 2008, 21:646.
30. Marcen R, del Castillo D, Capdevila L. Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain. Transplantation 2009, 87:1340.
31. Ruggenenti P, Perico N, Gotti E. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007, 84:956.
32. Pascual J, Bloom D, Torrealba J. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008, 8:1529.
33. Racusen LC. T-regulatory cells in human transplantation. Am J Transplant 2008, 8:1359.